Seven Grand Managers LLC Acquires New Stake in Capricor Therapeutics, Inc. $CAPR

Seven Grand Managers LLC acquired a new stake in Capricor Therapeutics, Inc. (NASDAQ:CAPR) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 100,000 shares of the biotechnology company’s stock, valued at approximately $2,886,000. Seven Grand Managers LLC owned about 0.22% of Capricor Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of CAPR. Vanguard Group Inc. grew its position in Capricor Therapeutics by 16.1% in the 4th quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock valued at $73,936,000 after buying an additional 355,161 shares during the last quarter. GSA Capital Partners LLP purchased a new position in Capricor Therapeutics in the 3rd quarter valued at $1,555,000. Moody Aldrich Partners LLC purchased a new position in Capricor Therapeutics in the 4th quarter valued at $6,025,000. Two Sigma Investments LP grew its position in Capricor Therapeutics by 128.3% in the 3rd quarter. Two Sigma Investments LP now owns 355,796 shares of the biotechnology company’s stock valued at $2,565,000 after buying an additional 199,959 shares during the last quarter. Finally, Raymond James Financial Inc. grew its position in Capricor Therapeutics by 1,629.9% in the 3rd quarter. Raymond James Financial Inc. now owns 191,292 shares of the biotechnology company’s stock valued at $1,379,000 after buying an additional 180,234 shares during the last quarter. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have commented on CAPR shares. B. Riley Financial raised their target price on Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a report on Friday, March 13th. Roth Mkm reissued a “buy” rating and issued a $38.00 target price on shares of Capricor Therapeutics in a report on Friday, May 15th. Piper Sandler reissued an “overweight” rating and issued a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. Cantor Fitzgerald set a $62.00 target price on Capricor Therapeutics and gave the company an “overweight” rating in a report on Friday, March 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $60.00 target price on shares of Capricor Therapeutics in a report on Wednesday, May 13th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Capricor Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $48.36.

Capricor Therapeutics Stock Performance

Capricor Therapeutics stock opened at $29.14 on Thursday. Capricor Therapeutics, Inc. has a one year low of $4.30 and a one year high of $40.37. The business has a fifty day moving average of $31.54 and a two-hundred day moving average of $25.62. The company has a market cap of $1.69 billion, a P/E ratio of -12.56 and a beta of 0.48.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). Sell-side analysts predict that Capricor Therapeutics, Inc. will post -0.75 EPS for the current year.

Insider Buying and Selling at Capricor Therapeutics

In other news, Director Karimah Es Sabar sold 61,265 shares of Capricor Therapeutics stock in a transaction on Tuesday, March 31st. The stock was sold at an average price of $30.17, for a total transaction of $1,848,365.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock in a transaction on Tuesday, March 31st. The stock was sold at an average price of $30.13, for a total value of $753,250.00. Following the transaction, the chief financial officer directly owned 8,223 shares of the company’s stock, valued at $247,758.99. This trade represents a 75.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 172,529 shares of company stock valued at $5,302,440 in the last ninety days. Corporate insiders own 9.20% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.